Price T Rowe Associates Inc. MD Sells 146,547 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Price T Rowe Associates Inc. MD reduced its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 4.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,903,025 shares of the company's stock after selling 146,547 shares during the period. Price T Rowe Associates Inc. MD owned 7.76% of Entrada Therapeutics worth $50,194,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in shares of Entrada Therapeutics by 8.8% in the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company's stock valued at $9,214,000 after acquiring an additional 46,512 shares during the last quarter. Barclays PLC increased its holdings in Entrada Therapeutics by 210.6% during the third quarter. Barclays PLC now owns 45,110 shares of the company's stock worth $720,000 after buying an additional 30,585 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Entrada Therapeutics during the fourth quarter worth $36,000. SG Americas Securities LLC lifted its stake in Entrada Therapeutics by 44.0% in the fourth quarter. SG Americas Securities LLC now owns 14,036 shares of the company's stock valued at $243,000 after acquiring an additional 4,291 shares during the last quarter. Finally, LPL Financial LLC increased its stake in shares of Entrada Therapeutics by 12.9% during the 4th quarter. LPL Financial LLC now owns 55,154 shares of the company's stock worth $954,000 after purchasing an additional 6,310 shares during the last quarter. 86.39% of the stock is owned by institutional investors.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock traded down $0.21 during trading hours on Monday, hitting $9.02. The company had a trading volume of 15,090 shares, compared to its average volume of 126,271. The firm has a 50-day moving average of $9.48 and a 200 day moving average of $14.01. The firm has a market cap of $342.34 million, a PE ratio of 5.67 and a beta of 0.04. Entrada Therapeutics, Inc. has a one year low of $7.10 and a one year high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The company had revenue of $12.25 million during the quarter, compared to analysts' expectations of $11.95 million. As a group, research analysts expect that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Monday, March 31st.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.